Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Operating Income (2016 - 2025)

Kiora Pharmaceuticals' Operating Income history spans 11 years, with the latest figure at -$7.3 million for Q4 2025.

  • For Q4 2025, Operating Income fell 185.03% year-over-year to -$7.3 million; the TTM value through Dec 2025 reached -$12.8 million, down 384.48%, while the annual FY2025 figure was -$12.8 million, 384.48% down from the prior year.
  • Operating Income reached -$7.3 million in Q4 2025 per KPRX's latest filing, down from -$794437.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $13.2 million in Q1 2024 to a low of -$7.3 million in Q4 2025.
  • Average Operating Income over 5 years is -$2.4 million, with a median of -$2.6 million recorded in 2024.
  • Peak YoY movement for Operating Income: crashed 444.73% in 2021, then surged 789.85% in 2024.
  • A 5-year view of Operating Income shows it stood at -$6.4 million in 2021, then surged by 41.88% to -$3.7 million in 2022, then soared by 42.79% to -$2.1 million in 2023, then decreased by 21.05% to -$2.6 million in 2024, then crashed by 185.03% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Operating Income are -$7.3 million (Q4 2025), -$794437.0 (Q3 2025), and -$2.4 million (Q2 2025).